According to Fintel, on May 24, 2023, BTIG upgraded their outlook for Organogenesis Holdings Inc – (NASDAQ:ORGO) from Neutral to Buy. The average one-year price target for Organogenesis Holdings Inc – is 11.22. The average price target represents an increase of 226.16% from its latest closing price of 3.44. This indicates a bullish outlook for the company, with the projected annual revenue for Organogenesis Holdings Inc – expected to increase by 10.75%.
The company offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics including orthopedics and spine.
There are 354 funds or institutions reporting positions in Organogenesis Holdings Inc -, representing a decrease of 13 owner(s) or 3.54% in the last quarter. The put/call ratio of ORGO is 1.54, indicating a bearish outlook.
Soleus Capital Management holds 9,853K shares representing 7.51% ownership of the company. IJR – iShares Core S&P Small-Cap ETF holds 5,308K shares representing 4.04% ownership of the company. Aqr Capital Management holds 2,552K shares representing 1.94% ownership of the company. Citadel Advisors holds 2,552K shares representing 1.94% ownership of the company. Federated Hermes holds 1,895K shares representing 1.44% ownership of the company.
Overall, the upgrade in BTIG’s outlook suggests favorable progress for Organogenesis Holdings Inc – in the near future.
Key filings for this company:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.